A prospective study about cytokine profiles in NSCLC patients receiving ICI treatment in the second line revealed that patients with elevated expression of IFN-γ significantly benefit from PD-1 blockers (61). This evidence concerns the gene IFNG and non-small cell lung carcinoma.